Last reviewed · How we verify
Isoniazid Aminosalicylate Tablets
Isoniazid and aminosalicylate work synergistically to inhibit mycobacterial cell wall synthesis and folate metabolism, killing Mycobacterium tuberculosis.
Isoniazid and aminosalicylate work synergistically to inhibit mycobacterial cell wall synthesis and folate metabolism, killing Mycobacterium tuberculosis. Used for Tuberculosis (pulmonary and extrapulmonary), Drug-resistant tuberculosis (as part of combination therapy).
At a glance
| Generic name | Isoniazid Aminosalicylate Tablets |
|---|---|
| Also known as | ethambutol tablets, pyrazinamide tablets, rifabutin capsules, moxifloxacin tablets |
| Sponsor | Shanghai Pulmonary Hospital, Shanghai, China |
| Drug class | Antituberculous agent combination |
| Target | Mycobacterial catalase-peroxidase (KatG), mycolic acid synthesis, folate metabolism |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Isoniazid is a prodrug that inhibits mycolic acid synthesis in the mycobacterial cell wall after activation by catalase-peroxidase. Aminosalicylate (para-aminosalicylic acid) inhibits folate synthesis and acts as a second-line agent. Together in a fixed-dose combination, they provide complementary bactericidal and bacteriostatic activity against tuberculosis.
Approved indications
- Tuberculosis (pulmonary and extrapulmonary)
- Drug-resistant tuberculosis (as part of combination therapy)
Common side effects
- Gastrointestinal disturbance (nausea, vomiting, diarrhea)
- Peripheral neuropathy
- Hepatotoxicity
- Hypersensitivity reactions
- Arthralgias
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: